Dova Pharmaceuticals, Inc. IPO Advisory
Share this IPO Profile:Smart Search
Company |
Symbol |
Price Range |
Issue Price |
Open |
Shares |
Trade Date |
| Dova Pharmaceuticals, Inc. | DOVA - NASDAQ |
$15.00-$17.00 | $17.00 | $19.25 | 4.41 million | 6/29/2017 |
| J.P. Morgan, Jefferies, Leerink Partners | ||||||
Co-Manager(s): | ||||||
| Health Care | ||||||
Filing(s): Filed 2017-06-02 Terms Added 2017-06-19 | ||||||
Dova Pharmaceuticals, Inc. Quote & Chart - Click for current quote - DOVA
IPO Boutique aggregates information on public companies and private companies, such as "DOVA" IPO, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry and obtain independent verification of factual statements before presenting them to our users. Be informed.
About Dova Pharmaceuticals, Inc. (adapted from Dova Pharmaceuticals, Inc. prospectus):
They are a pharmaceutical company focused on acquiring, developing and commercializing drug candidates for diseases that are treated by specialist physicians, with an initial focus on addressing thrombocytopenia, a disorder characterized by a low blood platelet count.
This description is adapted from prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus.
They are a pharmaceutical company focused on acquiring, developing and commercializing drug candidates for diseases that are treated by specialist physicians, with an initial focus on addressing thrombocytopenia, a disorder characterized by a low blood platelet count.
This description is adapted from prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus.
IPO Boutique aggregates information on public companies and private companies, such as "DOVA" IPO, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry and obtain independent verification of factual statements before presenting them to our users. Be informed.